STOCK TITAN

[6-K] AC Immune SA Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2025

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F      Form 40-F


This Report on Form 6-K (excluding Exhibit 99.3 herewith) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA

By:

/s/ Andrea Pfeifer

Name:  Andrea Pfeifer

Title:    Chief Executive Officer

By:

/s/ Christopher Roberts

Name:  Christopher Roberts

Title:    Chief Financial Officer

Date:     August 5, 2025


EXHIBIT INDEX

Exhibit
Number

    

Description

99.1

Interim Condensed Consolidated Financial Statements (Unaudited) (IFRS) as of and for the three and six months ended June 30, 2025

99.2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

99.3

Press Release dated August 5, 2025


FAQ

What information is available in AC Immune SA's August 2025 Form 6-K filing?

This document appears to contain limited substantive content.
AC Immune

NASDAQ:ACIU

ACIU Rankings

ACIU Latest News

ACIU Latest SEC Filings

ACIU Stock Data

213.27M
62.25M
38.01%
25.38%
1.39%
Biotechnology
Healthcare
Link
Switzerland
Lausanne